Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maiko Matsushita

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|August 5, 2021
[Immunogenic cell death in hematological malignancies]Maiko Matsushita
Cancers|November 13, 2021
Novel Treatment Strategies Utilizing Immune Reactions against Chronic Myelogenous Leukemia Stem CellsMaiko Matsushita
Journal of Oncology|December 1, 2018
Immunomodulatory Effects of Drugs for Effective Cancer ImmunotherapyMaiko Matsushita, Mai Kawaguchi
Cancers|January 28, 2026
Autophagy Modulates Immunogenic Cell Death in CancerMaiko Matsushita, Miyu Moriwaki
Therapeutic Innovation & Regulatory Science|May 2, 2018
Optimal Anti-cancer Drug Profiles for Effective Penetration of the Anti-cancer Drug Market by Generic Drugs in JapanShoyo Shibata, Maiko Matsushita, Yoshimasa Saito, et al.
Leukemia & Lymphoma|April 12, 2003
Preferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological malignanciesMaiko Matsushita, Rie Yamazaki, Hideyuki Ikeda, et al.
Therapeutic Innovation & Regulatory Science|May 2, 2018
Anticancer Drug Prescription Patterns in Japan: Future Directions in Cancer TherapyShoyo Shibata, Maiko Matsushita, Yoshimasa Saito, et al.
Nihon Rinsho. Japanese Journal of Clinical Medicine|December 25, 2012
[Immunotherapy targeting cancer stem cells]Yutaka Kawakami, Maiko Matsushita, Ryo Ueda, et al.
Vaccines|October 7, 2020
Characteristics of a Novel Target Antigen Against Myeloma Cells for ImmunotherapyMaiko Matsushita, Saku Saito, Shinya Yokoe, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 24, 2009
Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradicationXiao-Song Zhong, Maiko Matsushita, Jason Plotkin, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|August 5, 2021
[Immunogenic cell death in hematological malignancies]Maiko Matsushita
Cancers|November 13, 2021
Novel Treatment Strategies Utilizing Immune Reactions against Chronic Myelogenous Leukemia Stem CellsMaiko Matsushita
Journal of Oncology|December 1, 2018
Immunomodulatory Effects of Drugs for Effective Cancer ImmunotherapyMaiko Matsushita, Mai Kawaguchi
Cancers|January 28, 2026
Autophagy Modulates Immunogenic Cell Death in CancerMaiko Matsushita, Miyu Moriwaki
Therapeutic Innovation & Regulatory Science|May 2, 2018
Optimal Anti-cancer Drug Profiles for Effective Penetration of the Anti-cancer Drug Market by Generic Drugs in JapanShoyo Shibata, Maiko Matsushita, Yoshimasa Saito, et al.
Leukemia & Lymphoma|April 12, 2003
Preferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological malignanciesMaiko Matsushita, Rie Yamazaki, Hideyuki Ikeda, et al.
Therapeutic Innovation & Regulatory Science|May 2, 2018
Anticancer Drug Prescription Patterns in Japan: Future Directions in Cancer TherapyShoyo Shibata, Maiko Matsushita, Yoshimasa Saito, et al.
Nihon Rinsho. Japanese Journal of Clinical Medicine|December 25, 2012
[Immunotherapy targeting cancer stem cells]Yutaka Kawakami, Maiko Matsushita, Ryo Ueda, et al.
Vaccines|October 7, 2020
Characteristics of a Novel Target Antigen Against Myeloma Cells for ImmunotherapyMaiko Matsushita, Saku Saito, Shinya Yokoe, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 24, 2009
Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradicationXiao-Song Zhong, Maiko Matsushita, Jason Plotkin, et al.
Pageof 3